Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

FDA external report recommends actions to address US opioid crisis

Over 100,000 Americans died from a drug overdose in 2021, with 70,000 of those due to opioids

- PMLiVE

Merck reports positive results for Keytruda combination in phase 3 gastric cancer trial

Over one million new cases of gastric cancer were diagnosed globally in 2020

- PMLiVE

Gates MRI and Calibr announce licensing agreement for tuberculosis treatment

TB is a severe disease responsible for an estimated 1.5 million deaths per year

- PMLiVE

Results for GSK’s RSV vaccine candidate published in New England Journal of Medicine

RSV infections in older adults account for around 6,000 to 10,000 deaths in the US each year

- PMLiVE

LifeArc’s challenge to combat bronchiectasis

PME talks to Catherine Kettleborough about the charity’s new £100m programme to fast-track scientific discoveries into new healthcare solutions

Origins’ Strategy Offering Explained

What do we mean when we say that at Origins, we provide patient focused strategies throughout the product lifecycle? In this short video Origins’ Director Su Smith explains our strategy...

Origins – The Patient Focused Specialists

- PMLiVE

Uptake Strategies opens applications for interactive graduate event

The academy will help 1,000 graduates begin their careers in the pharma and biotech industry

- PMLiVE

AstraZeneca and MSD report final overall survival results from prostate cancer study

The combination treatment increased the current patient survival rate by over seven months

- PMLiVE

Janssen reports updated phase 3 results for niraparib combination in prostate cancer

Prostate cancer is the most common cancer affecting men in Europe

- PMLiVE

FDA panel backs over-the-counter use of Emergent BioSolutions’ Narcan

The nasal spray works by blocking the effects of an opioid overdose if administered in time

- PMLiVE

Pfizer’s Talzenna combination shows promise in phase 3 prostate cancer study

10-20% of patients develop metastatic prostate cancer within five to seven years of diagnosis

- PMLiVE

Facts are stubborn things

California tried to tell doctors what would be classified as misinformation – it didn’t go well

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links